Scarica l'app Stockscreener
221.89
0.52%
1.14
Pre-mercato:
222.04
0.15
+0.07%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ABBV Giù?
Forum
Previsione
Storia dei dividendi
Precedente Chiudi:
$220.75
Aprire:
$221
Volume 24 ore:
8.36M
Relative Volume:
1.46
Capitalizzazione di mercato:
$392.16B
Reddito:
$59.64B
Utile/perdita netta:
$2.36B
Rapporto P/E:
167.43
EPS:
1.3253
Flusso di cassa netto:
$19.68B
1 W Prestazione:
-4.94%
1M Prestazione:
-0.64%
6M Prestazione:
+15.86%
1 anno Prestazione:
+26.40%
Intervallo 1D:
$217.00
$223.34
Intervallo di 1 settimana:
$215.85
$231.54
Portata 52W:
$164.39
$244.81
Abbvie Inc Stock (ABBV) Company Profile
Nome
Abbvie Inc
Settore
Industria
Telefono
(847) 932-7900
Indirizzo
1 NORTH WAUKEGAN ROAD, NORTH CHICAGO, IL
Confronta ABBV con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ABBV
Abbvie Inc
|
221.89 | 390.15B | 59.64B | 2.36B | 19.68B | 1.3253 |
|
LLY
Lilly Eli Co
|
1,073.29 | 964.11B | 59.42B | 18.41B | 6.44B | 20.22 |
|
JNJ
Johnson Johnson
|
218.55 | 514.75B | 92.15B | 25.12B | 20.46B | 10.36 |
|
NVS
Novartis Ag Adr
|
146.16 | 271.72B | 54.45B | 14.42B | 17.15B | 7.333 |
|
MRK
Merck Co Inc
|
111.01 | 268.70B | 63.90B | 19.05B | 13.05B | 7.5596 |
Abbvie Inc Stock (ABBV) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-08 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| 2026-01-07 | Ripresa | UBS | Neutral |
| 2025-12-10 | Aggiornamento | HSBC Securities | Hold → Buy |
| 2025-11-13 | Iniziato | Scotiabank | Sector Outperform |
| 2025-11-04 | Downgrade | DZ Bank | Buy → Hold |
| 2025-10-14 | Downgrade | Erste Group | Buy → Hold |
| 2025-10-01 | Downgrade | HSBC Securities | Buy → Hold |
| 2025-09-17 | Aggiornamento | Berenberg | Hold → Buy |
| 2025-08-12 | Ripresa | Piper Sandler | Overweight |
| 2025-08-07 | Aggiornamento | Daiwa Securities | Neutral → Outperform |
| 2025-05-14 | Downgrade | Citigroup | Buy → Neutral |
| 2025-04-22 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-12-10 | Ripresa | BofA Securities | Neutral |
| 2024-12-05 | Downgrade | Daiwa Securities | Outperform → Neutral |
| 2024-11-22 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2024-11-15 | Iniziato | Wolfe Research | Outperform |
| 2024-11-04 | Aggiornamento | Argus | Hold → Buy |
| 2024-10-17 | Iniziato | Bernstein | Mkt Perform |
| 2024-06-05 | Aggiornamento | HSBC Securities | Hold → Buy |
| 2024-05-17 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-01-29 | Aggiornamento | William Blair | Mkt Perform → Outperform |
| 2023-12-18 | Downgrade | HSBC Securities | Buy → Hold |
| 2023-12-11 | Aggiornamento | Goldman | Neutral → Buy |
| 2023-11-09 | Iniziato | Deutsche Bank | Hold |
| 2023-10-30 | Aggiornamento | Barclays | Equal Weight → Overweight |
| 2023-10-20 | Ripresa | UBS | Neutral |
| 2023-09-29 | Iniziato | Raymond James | Outperform |
| 2023-07-25 | Iniziato | William Blair | Mkt Perform |
| 2023-07-14 | Iniziato | HSBC Securities | Buy |
| 2023-04-05 | Downgrade | Argus | Buy → Hold |
| 2023-03-01 | Iniziato | Guggenheim | Buy |
| 2023-02-22 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| 2023-02-10 | Aggiornamento | SVB Securities | Underperform → Market Perform |
| 2022-11-18 | Iniziato | Credit Suisse | Outperform |
| 2022-11-08 | Downgrade | Societe Generale | Buy → Hold |
| 2022-08-01 | Downgrade | Atlantic Equities | Overweight → Neutral |
| 2022-05-23 | Iniziato | SVB Leerink | Underperform |
| 2022-05-06 | Downgrade | Daiwa Securities | Outperform → Neutral |
| 2022-04-06 | Ripresa | Morgan Stanley | Overweight |
| 2022-02-28 | Downgrade | UBS | Buy → Neutral |
| 2022-02-03 | Reiterato | BMO Capital Markets | Outperform |
| 2022-02-03 | Reiterato | Barclays | Equal Weight |
| 2022-02-03 | Reiterato | BofA Securities | Neutral |
| 2022-02-03 | Reiterato | Goldman | Neutral |
| 2022-01-13 | Iniziato | Redburn | Buy |
| 2022-01-12 | Reiterato | BMO Capital Markets | Outperform |
| 2021-12-09 | Ripresa | Wells Fargo | Overweight |
| 2021-11-23 | Aggiornamento | Societe Generale | Hold → Buy |
| 2021-07-27 | Ripresa | Truist | Buy |
| 2021-04-07 | Ripresa | RBC Capital Mkts | Outperform |
| 2020-11-10 | Ripresa | Bernstein | Outperform |
| 2020-09-29 | Iniziato | Berenberg | Hold |
| 2020-06-23 | Aggiornamento | Atlantic Equities | Neutral → Overweight |
| 2020-06-09 | Aggiornamento | Wolfe Research | Peer Perform → Outperform |
| 2020-06-02 | Aggiornamento | Argus | Hold → Buy |
| 2020-05-18 | Ripresa | BofA/Merrill | Neutral |
| 2020-05-12 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2020-05-11 | Ripresa | Morgan Stanley | Overweight |
| 2020-04-20 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2020-03-23 | Downgrade | Societe Generale | Buy → Hold |
| 2020-02-27 | Iniziato | Barclays | Equal Weight |
| 2020-02-06 | Iniziato | Mizuho | Buy |
| 2020-01-07 | Iniziato | RBC Capital Mkts | Sector Perform |
| 2019-12-26 | Reiterato | Cowen | Outperform |
| 2019-09-26 | Aggiornamento | Citigroup | Neutral → Buy |
| 2019-08-20 | Aggiornamento | Piper Jaffray | Neutral → Overweight |
| 2019-06-27 | Aggiornamento | Wolfe Research | Underperform → Peer Perform |
| 2019-06-26 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
| 2019-05-28 | Iniziato | Goldman | Neutral |
| 2019-04-29 | Aggiornamento | BMO Capital Markets | Underperform → Market Perform |
Mostra tutto
Abbvie Inc Borsa (ABBV) Ultime notizie
Conning Inc. Decreases Position in AbbVie Inc. $ABBV - MarketBeat
AbbVie: stepping up obesity treatments with an alternative approach to GLP-1 - marketscreener.com
Rep. Julia Letlow Sells Off Shares of AbbVie Inc. (NYSE:ABBV) - MarketBeat
AbbVie stock in focus after hours as it eyes obesity market — what to watch next - TechStock²
AbbVie Seeks To Grow Obesity Drug Portfolio — Retail Touts Drugmaker As Big Competition To Lilly - Stocktwits
Top Research Reports for AbbVie, Intel & Boeing - Yahoo Finance
AbbVie plans to build out its presence in obesity market - Reuters
AbbVie Reaches Agreement With Trump Administration, Joining MFN Initiatives - Pharmacy Times
AbbVie to invest $100 billion in the U.S in exchange for tariff exemptions - The American Bazaar
JP Morgan 2026: AbbVie Advances its Pipeline - PharmExec.com
Key facts: AbbVie Reports Growth in Immunology, Neuroscience; Targets Weight-Loss Market - TradingView — Track All Markets
AbbVie sets sights on immunology, neurology dominance - Crain's Chicago Business
AbbVie Bets Big on Chinese Cancer Drug in $5.6 Billion Licensing Deal - Caixin Global
AbbVie Joins TrumpRx in Exchange for Tariff Relief and Pricing Flexibility - Pharmaceutical Commerce
AbbVie (ABBV) Rises on Agreement for Drug Pricing and Investment Commitment - GuruFocus
Wall Street Bulls Look Optimistic About AbbVie (ABBV): Should You Buy? - Yahoo Finance
Stephens Inc. AR Boosts Position in AbbVie Inc. $ABBV - MarketBeat
Retirement Planning Group LLC Buys 6,958 Shares of AbbVie Inc. $ABBV - MarketBeat
Kera Capital Partners Inc. Makes New Investment in AbbVie Inc. $ABBV - MarketBeat
AbbVie’s Trump Deal Unlocks US$100bn for R&D & Manufacturing - Manufacturing Digital
Robeco Schweiz AG Decreases Stock Position in AbbVie Inc. $ABBV - MarketBeat
AbbVie To Buy Device Manufacturing Facility From West Pharmaceutical Services - Med Device Online
AbbVie inks USD 5.6bn global licensing deal with Chinese biotech for cancer therapy - medwatch.com
AbbVie strikes deal with Trump, pledges USD 100bn investment over 10 years - medwatch.com
Trump administration strikes deal with AbbVie to cut costs of certain drugs - KCRA
Revolution Medicines Dismisses Merck, Abbvie Buyout Talks While Analyst Say It Is Worth More Than $32B - Stocktwits
Key facts: AbbVie signs Medicaid deal; banker charged with insider trading; UAE launches mental health campaign - TradingView — Track All Markets
AbbVie and Trump administration reach agreement on drug prices, tariffs - Daily Herald
AbbVie news: Trump administration strikes deal with North Chicago-based company to cut costs of certain drugs - ABC7 Chicago
Systemic Lupus Erythematosus Market to Exhibit Growth at a CAGR of 9.4% During the Forecast Period (2025–2034) Owing to Rising Use of Biologics – Approvals of BENLYSTA and SAPHNELO, Plus a Strong Pipeline | DelveInsight - GlobeNewswire Inc.
AbbVie Signs US Deal to Cut Drug Prices, Secure Tariff Exemptions - TradingView — Track All Markets
10 Health Care Stocks Whale Activity In Today's Session - Benzinga
ABBV Inks Drug Pricing Deal With Trump, Joins PD-1xVEGF Bandwagon - TradingView — Track All Markets
Will AbbVie's Oncology Segment Support Top-line Growth in Q4 Earnings? - The Globe and Mail
AbbVie, RemeGen Partner on Novel Bispecific Antibody for Advanced Tumors - Contract Pharma
Investors Heavily Search AbbVie Inc. (ABBV): Here is What You Need to Know - Yahoo Finance
AbbVie’s $100 Billion Gamble: A Strategic Trade With Washington to Lower Drug Costs - abacusnews.com
AbbVie Secures Tariff Relief Pact - GuruFocus
AbbVie pledges $100B to US production in drug pricing deal with Trump - BioPharma Dive
AbbVie and China’s RemeGen kick off year with $5.6bn oncology deal - BioXconomy
Polaris Capital Management LLC Cuts Position in AbbVie Inc. $ABBV - MarketBeat
AbbVie Commits $100B in US R&D, Manufacturing, Winning Tariff, Pricing Exemptions - BioSpace
AbbVie reaches 3-year deal with White House to lower drug prices - MSN
Nordea Investment Management AB Raises Stock Position in AbbVie Inc. $ABBV - MarketBeat
AbbVie inks MFN drug pricing deal, pledges $100bn to US R&D - Pharmaceutical Technology
AbbVie adds Arizona plant to $10bn US manufacturing push - The Pharma Letter
Abbvie, US reach agreement to cut drug prices - WHTC
AbbVie Stock Rises After $100 Billion Deal With Trump. It Will Avoid Tariffs. - Barron's
ZAWYA-PRESSR: Ministry of Health and Prevention launches "Mental Health 360" campaign in collaboration with AbbVie - TradingView — Track All Markets
Remegen stock rating upgraded by JPMorgan on AbbVie licensing deal - Investing.com Canada
AbbVie reaches deal with Trump administration on drug prices in exchange for tariff relief - Yahoo Finance
Abbvie Inc Azioni (ABBV) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.21%
1.22%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):